The Canadian government has allowed a startup to export psychedelic substances for medical use to Australia. Optimi Health Corp. has been tasked with exporting pills containing psilocybin, a magic mushroom extract, and MDMA, as approved by the health department.
The growing demand for these substances isn’t limited to magic mushrooms Ontario within Canada. Other countries are following Canada’s lead, exploring and allowing serotogenic compounds for medicinal applications.
Feel confident to buy psychedelics online in Canada and tap into your inherent potential through trusted sources.
[toc]Main Takeaways:
- Optimi Health, a Vancouver-based startup, has been issued a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment protocol involves three sessions over a period of five to eight weeks, with each session lasting around eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its certification to broaden the pharmaceutical market for psychedelic substances and secure a first-mover advantage.
Seven companies have exported psilocybin, MDMA, or both, but these exports were solely for clinical trial purposes. A representative from Canada’s health department could not confirm whether these exports were for regular patient use, and declined to name the companies due to privacy issues.
This accomplishment places Optimi among a small number of global suppliers, with the current market favoring clinical over recreational use.
What Does the Pill Contain?
Although the company has not disclosed the specific type of mushroom used in the pill, they work with various strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint community, home to roughly 3,000 people, is situated three hours east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
Approximately one in five Australians aged between 16 and 85 are projected to encounter a mental health disorder. PTSD (post-traumatic stress disorder) is expected to impact 11% of Australians at some time in their life, while anxiety disorders are common in 17% of the population.
There’s a vast array of techniques for treating mental health issues, but not all are effective for everyone. Those patients who don’t find relief from specific treatments may struggle to find a method that works for them, leading to increased vulnerability.
Decoding the Process
Australia has been at the forefront of psilocybin usage, allowing certified psychiatrists to use this regulated substance in the treatment of PTSD and treatment-resistant depression.
In an unexpected move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic purposes. The TGA declared these substances safe when used in a medical setting for patients with severe mental disorders.
This advancement has been groundbreaking for many mental health professionals and researchers. The usage of these substances will be strictly monitored; it’s not just a case of taking a pill and walking away.
The treatment regimen typically includes three sessions over a span of five to eight weeks. Each session lasts around eight hours, with the therapist present with the patient for the entire duration.
Canada’s Role in Psilocybin Research
Canada has stepped up as a leading center for psilocybin research, greatly expanding our understanding of this substance. Health Canada, in collaboration with various institutions, is leading the charge in investigating psilocybin’s therapeutic potential in treating a range of mental health conditions.
Research institutions are no longer required to label these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to grow shrooms for research purposes.
Having legal access to substances previously deemed harmful enables researchers to deepen their understanding of potential benefits for many individuals.
A Recurring Trend
The potential of this particular field was first tapped in the 1950s for addressing mental health challenges and substance abuse disorders, including alcoholism. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer spearheaded this pioneering research at the Weyburn. Remarkable progress was made at The Saskatchewan Mental Hospital under the leadership of then-premier Tommy Douglas, who empowered the medical fraternity with significant autonomy to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer embarked on investigations using LSD, mescaline, and peyote as potential alternatives to the harsh practices of electroshock and lobotomy. Their research took unexpected turns, with the pair advocating for medical professionals, nurses, and support staff to experiment with these drugs.
Canadian Institutes of Health Research
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Project Budget |
| A randomized controlled trial | Emotional distress at end-of-life in patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms underpinning psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a more in-depth understanding of the benefits of regulated substances. This has been made possible by the Canadian Drugs and Substances Strategy (CDSS), an initiative of the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have started a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment comprises three eight-hour sessions with MDMA, spaced a month apart, and nine short sessions of 90 minutes without the drug. Researchers consider this trial to be of historical importance as it is the first clinical investigation of an illegal
It’s been over four decades since such a psychedelic substance has been discovered.
Comprehending Psilocybin
Psilocybin is a naturally occurring psychedelic compound, which is found in certain species of mushrooms. Once ingested, it is metabolized into psilocin. This psilocin then activates the serotonin 5-HT2a receptors that are situated on the cortical pyramidal cells in the brain, the key processing sites.
The substance is currently under study by local authorities for its potential to aid with conditions such as depression, anxiety, addiction, and end-of-life distress, by encouraging introspection and spiritual enlightenment.
Why is it Potentially Beneficial for Depression, PTSD, and More?
The active component targets several areas in the brain, making it potentially useful for a range of mental disorders. A number of patients in Canada and Australia have already been treated using this therapy. The results so far are promising, with a few mild side effects such as temporary anxiety or elevated blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound partially stimulates serotonin receptors, especially the 5-HT2A subtype, which plays a key role in regulating mood and processing emotions.
- Modulation of Default Mode Network (DMN): It reduces activity in the DMN, promoting introspection, mitigating rigid thought patterns, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the compound are due to its influence on the prefrontal and limbic regions of the brain, including the amygdala. In individuals suffering from depression, there is typically a reduced response to emotional stimuli. This compound boosts the response to positive emotional stimuli in the right amygdala, while moderating the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: It cultivates feelings of euphoria, interconnectedness, and emotional openness both during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience may allow individuals to safely address and process deeply embedded emotions, traumatic memories, or existential concerns in a supportive environment.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that this can result in lasting beneficial changes, such as improved wellness, enhanced satisfaction in life, and spiritual growth.
What Can You Discover at Your Neighbourhood Magic Mushroom Shop?
Interested in how this substance could impact your mental health? Explore magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, encourages creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and enhances overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes clarity, creativity, and concentration. Contains a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
International Acknowledgement of Psilocybin
Canada is not the sole country promoting the use of magic mushrooms to address mental health concerns. Countries like Australia also endorse the use of these hallucinogens for treating conditions such as depression and PTSD. They procure top-grade psychedelic capsules from trustworthy sources. With proper supervision, patients can significantly improve their life quality. 3 Amigos Canada, a magic mushroom supplier, offers a variety of products, from capsules to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic potential in enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is beneficial for treating depression and addiction.
Conversely, MDMA promotes empathy and is effective in PTSD therapy. It demonstrates potential in improving emotional processing and
Despite its classification as a controlled substance, this treatment option has shown promising therapeutic results.
Is this treatment option accessible to all Australians?
Not necessarily. In Australia, an individual’s eligibility for using this substance is assessed first. The assessment looks into various factors such as pre-existing heart conditions, any history of psychosis, and more. This treatment is solely available for patients who haven’t found relief from traditional treatments for ailments such as depression, anxiety, or PTSD.
What are the implications of Canada exporting mushrooms?
By exporting mushrooms, Canada is aiming to take a leading position in the psychedelics market, mirroring its stance on cannabis. This could open doors for more companies to produce high-quality products. As a result, Canada could potentially lead the hallucinogen market, strengthen its economy, and increase the availability of treatments in other countries. Furthermore, it could prevent these countries from procuring their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles That Might Interest You:
